Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > BUSINESS
BUSINESS
- [Data] Sales of ASKA's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Nippon Chemiphar's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Wakamoto's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Torii’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- Regulatory Challenges Remain for Introduction of Combination Vaccines: MSD VP Shirasawa
December 12, 2012
- Fycompa Approved for Use under NHS Scotland: Eisai
December 12, 2012
- Santen to Set Up Demand-Chain Strategic Planning Office
December 12, 2012
- Astellas, UMN Complete Administration of Seasonal Vaccine to Participants in Domestic PIII Trial
December 12, 2012
- Meta-Analysis of Study Data Finds 39% Overall Response Rate with Velcade Retreatment: Takeda
December 12, 2012
- Hisamitsu, Asahi Kasei Pharma to Comarket OAB Transdermal Drug
December 11, 2012
- Mochida Revving Up Collaboration Efforts in Biosimilars
December 11, 2012
- Otsuka Pharmaceutical Factory to Establish Infusion Products Subsidiary in India
December 11, 2012
- Ethical Drug Sales Up 6.1% in October: Crecon Report
December 11, 2012
- Feburic’s Market Share to Exceed 50% in Near Future: Teijin President Ohyagi
December 11, 2012
- Mylan Applies for Ciclosporin for Additional Indication Based on Data from Public Domain
December 11, 2012
- Teva Pharma Halts Sales of Pinatos Due to GMP Non-Compliance of South Korean Supplier
December 10, 2012
- JT Submits NDA for Anti-HIV Combination Drug, 1st NDA for Compound It Discovered
December 10, 2012
- US FDA Accepts NDA for Tacrolimus Extended-Release Capsules: Astellas
December 10, 2012
- Actavis Eyes 3 Monoclonal Antibodies for Entry into Japanese Biosimilar Market: EVP
December 10, 2012
- IP High Court Reverses JPO Ruling on Lipitor Patent
December 7, 2012
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…